Logo image of STOK

STOKE THERAPEUTICS INC (STOK) Stock Fundamental Analysis

NASDAQ:STOK - Nasdaq - US86150R1077 - Common Stock - Currency: USD

13.1  -0.15 (-1.13%)

After market: 13.1 0 (0%)

Fundamental Rating

5

Taking everything into account, STOK scores 5 out of 10 in our fundamental rating. STOK was compared to 551 industry peers in the Biotechnology industry. STOK is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. STOK has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

STOK had positive earnings in the past year.
STOK had a positive operating cash flow in the past year.
STOK had negative earnings in each of the past 5 years.
In the past 5 years STOK always reported negative operating cash flow.
STOK Yearly Net Income VS EBIT VS OCF VS FCFSTOK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

STOK's Return On Assets of 12.36% is amongst the best of the industry. STOK outperforms 95.46% of its industry peers.
With an excellent Return On Equity value of 14.36%, STOK belongs to the best of the industry, outperforming 94.92% of the companies in the same industry.
STOK has a better Return On Invested Capital (8.34%) than 94.01% of its industry peers.
Industry RankSector Rank
ROA 12.36%
ROE 14.36%
ROIC 8.34%
ROA(3y)-39.36%
ROA(5y)-34.31%
ROE(3y)-53.05%
ROE(5y)-43.36%
ROIC(3y)N/A
ROIC(5y)N/A
STOK Yearly ROA, ROE, ROICSTOK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

STOK has a Profit Margin of 26.33%. This is amongst the best in the industry. STOK outperforms 96.19% of its industry peers.
With an excellent Operating Margin value of 20.03%, STOK belongs to the best of the industry, outperforming 95.46% of the companies in the same industry.
Industry RankSector Rank
OM 20.03%
PM (TTM) 26.33%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
STOK Yearly Profit, Operating, Gross MarginsSTOK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

More info and screens

8

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so STOK is destroying value.
STOK has more shares outstanding than it did 1 year ago.
The number of shares outstanding for STOK has been increased compared to 5 years ago.
There is no outstanding debt for STOK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
STOK Yearly Shares OutstandingSTOK Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
STOK Yearly Total Debt VS Total AssetsSTOK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 8.10 indicates that STOK is not in any danger for bankruptcy at the moment.
STOK has a better Altman-Z score (8.10) than 83.67% of its industry peers.
There is no outstanding debt for STOK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 8.1
ROIC/WACC0.75
WACC11.13%
STOK Yearly LT Debt VS Equity VS FCFSTOK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 8.41 indicates that STOK has no problem at all paying its short term obligations.
STOK has a better Current ratio (8.41) than 72.41% of its industry peers.
A Quick Ratio of 8.41 indicates that STOK has no problem at all paying its short term obligations.
STOK has a Quick ratio of 8.41. This is in the better half of the industry: STOK outperforms 72.41% of its industry peers.
Industry RankSector Rank
Current Ratio 8.41
Quick Ratio 8.41
STOK Yearly Current Assets VS Current LiabilitesSTOK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 136.04% over the past year.
STOK shows a strong growth in Revenue. In the last year, the Revenue has grown by 2332.57%.
EPS 1Y (TTM)136.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%447.37%
Revenue 1Y (TTM)2332.57%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%3661.12%

3.2 Future

STOK is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.68% yearly.
The Revenue is expected to grow by 64.04% on average over the next years. This is a very strong growth
EPS Next Y103.64%
EPS Next 2Y-29.76%
EPS Next 3Y-10.68%
EPS Next 5Y15.68%
Revenue Next Year900.22%
Revenue Next 2Y26.95%
Revenue Next 3Y37.33%
Revenue Next 5Y64.04%

3.3 Evolution

STOK Yearly Revenue VS EstimatesSTOK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
STOK Yearly EPS VS EstimatesSTOK Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

STOK is valuated correctly with a Price/Earnings ratio of 15.06.
Compared to the rest of the industry, the Price/Earnings ratio of STOK indicates a rather cheap valuation: STOK is cheaper than 94.74% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 26.48. STOK is valued slightly cheaper when compared to this.
The Forward Price/Earnings Ratio is negative for STOK. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 15.06
Fwd PE N/A
STOK Price Earnings VS Forward Price EarningsSTOK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of STOK indicates a rather cheap valuation: STOK is cheaper than 98.19% of the companies listed in the same industry.
STOK's Price/Free Cash Flow ratio is rather cheap when compared to the industry. STOK is cheaper than 97.10% of the companies in the same industry.
Industry RankSector Rank
P/FCF 10.34
EV/EBITDA 7.03
STOK Per share dataSTOK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
STOK's earnings are expected to decrease with -10.68% in the coming years. This may justify a cheaper valuation.
PEG (NY)0.15
PEG (5Y)N/A
EPS Next 2Y-29.76%
EPS Next 3Y-10.68%

More info and screens

0

5. Dividend

5.1 Amount

STOK does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

STOKE THERAPEUTICS INC

NASDAQ:STOK (8/8/2025, 8:07:51 PM)

After market: 13.1 0 (0%)

13.1

-0.15 (-1.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)08-12 2025-08-12/amc
Inst Owners110.61%
Inst Owner Change-5.98%
Ins Owners4.36%
Ins Owner Change4.55%
Market Cap715.26M
Analysts84.71
Price Target23.69 (80.84%)
Short Float %22.08%
Short Ratio17.36
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)312.62%
Min EPS beat(2)66.58%
Max EPS beat(2)558.67%
EPS beat(4)4
Avg EPS beat(4)164.56%
Min EPS beat(4)13.51%
Max EPS beat(4)558.67%
EPS beat(8)7
Avg EPS beat(8)85.13%
EPS beat(12)11
Avg EPS beat(12)60.94%
EPS beat(16)11
Avg EPS beat(16)26.37%
Revenue beat(2)2
Avg Revenue beat(2)1046.03%
Min Revenue beat(2)417.96%
Max Revenue beat(2)1674.1%
Revenue beat(4)4
Avg Revenue beat(4)545.19%
Min Revenue beat(4)43.23%
Max Revenue beat(4)1674.1%
Revenue beat(8)6
Avg Revenue beat(8)252.14%
Revenue beat(12)10
Avg Revenue beat(12)182.11%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-6.28%
EPS NQ rev (1m)-4.31%
EPS NQ rev (3m)-34.3%
EPS NY rev (1m)0%
EPS NY rev (3m)103.56%
Revenue NQ rev (1m)-10.59%
Revenue NQ rev (3m)-16.41%
Revenue NY rev (1m)6.32%
Revenue NY rev (3m)298.39%
Valuation
Industry RankSector Rank
PE 15.06
Fwd PE N/A
P/S 3.75
P/FCF 10.34
P/OCF 10.29
P/B 2.04
P/tB 2.04
EV/EBITDA 7.03
EPS(TTM)0.87
EY6.64%
EPS(NY)-2.83
Fwd EYN/A
FCF(TTM)1.27
FCFY9.67%
OCF(TTM)1.27
OCFY9.72%
SpS3.5
BVpS6.41
TBVpS6.41
PEG (NY)0.15
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 12.36%
ROE 14.36%
ROCE 10.56%
ROIC 8.34%
ROICexc 619.21%
ROICexgc 619.21%
OM 20.03%
PM (TTM) 26.33%
GM N/A
FCFM 36.25%
ROA(3y)-39.36%
ROA(5y)-34.31%
ROE(3y)-53.05%
ROE(5y)-43.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 16.4%
Cap/Sales 0.18%
Interest Coverage 250
Cash Conversion 172.42%
Profit Quality 137.65%
Current Ratio 8.41
Quick Ratio 8.41
Altman-Z 8.1
F-Score8
WACC11.13%
ROIC/WACC0.75
Cap/Depr(3y)110.09%
Cap/Depr(5y)114.39%
Cap/Sales(3y)16.96%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)136.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%447.37%
EPS Next Y103.64%
EPS Next 2Y-29.76%
EPS Next 3Y-10.68%
EPS Next 5Y15.68%
Revenue 1Y (TTM)2332.57%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%3661.12%
Revenue Next Year900.22%
Revenue Next 2Y26.95%
Revenue Next 3Y37.33%
Revenue Next 5Y64.04%
EBIT growth 1Y132.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year52.82%
EBIT Next 3Y10.49%
EBIT Next 5Y17.28%
FCF growth 1Y177.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y181.13%
OCF growth 3YN/A
OCF growth 5YN/A